Galena Biopharma (GALE) Reports Q4 Loss Per Share of 6c, Reiterates FY15 Rev. Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Galena Biopharma (GALE) PT Lowered at Needham & Company But Still Sees Shares Doubling
March 6, 2015 10:00 AM ESTNeedham & Company analyst Chad Messer lowered his price target on Galena Biopharma (NASDAQ: GALE) to $4.00 (from $7.00) but maintained his Buy rating. The new price target represents 100% upside from yesterday's closing price.
Messer commented, "Abstral put in its best quarter since launch with $3.2... More
Roth Affirms Galena Biopharma (GALE) at 'Buy' Following Q4 Report; Still Sees FY15/FY16 as Busy Time Frame
March 6, 2015 8:42 AM ESTRoth Capital reiterates its Buy rating and $8 price target on Galena Biopharma (Nasdaq: GALE) following Q4, FY14 results reported Thursday night.
Analyst Joseph Pantginis noted that Galena's FY14 revenue of $9.32 million and loss of $0.31 per share compare with the firm's outlook calling for revenue of $8.5 million and loss of $0.35 per share.
Pantginis offered the following post-report commentary: 2015 represents a... More
